Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T18:19:25.938Z Has data issue: false hasContentIssue false
  • English
  • Français

“Pulse” Nasal Mupirocin Maintenance Regimen in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Published online by Cambridge University Press:  02 January 2015

Joseph M. Mylotte ,
Lucinda Kahler  and
Ellen Jackson
Joseph M. Mylotte*
Affiliation:
Departments of Medicine and Microbiology, the School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Erie County Medical Center, Buffalo, New York Department of Medicine, Erie County Medical Center, Buffalo, New York
Lucinda Kahler
Affiliation:
Department of Medicine, Erie County Medical Center, Buffalo, New York
Ellen Jackson
Affiliation:
Department of Medicine, Erie County Medical Center, Buffalo, New York
*
Infectious Diseases, Erie County Medical Center, 462 Grider St, Buffalo, NY 14215
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To determine, among patients undergoing continuous ambulatory peritoneal dialysis (CAPD) who were Staphylococcus aureus nasal carriers, if periodic brief “pulses” of nasal mupirocin calcium ointment 2% after completion of a mupirocin eradication protocol would maintain these patients free of carriage.

Design:

Noncomparative, nonblinded study with historical controls.

Setting:

A county medical center.

Patients:

Patients in a CAPD program during the period April 1996 to May 1998.

Methods:

All patients in the CAPD program had monthly nasal cultures for S aureus. After informed consent, S aureus nasal carriers were administered mupirocin to the nares twice a day for 5 days followed by nasal mupirocin twice monthly. Peritonitis and exit-site infection rates were monitored independently by CAPD nursing staff. Patients were monitored monthly for adverse effects of mupirocin and compliance with the maintenance regimen.

Results:

Twenty-four patients in the CAPD program were enrolled in the study and had a median duration of follow-up of 8.5 months. Fifteen (63%) of the 24 patients remained free of nasal carriage on follow-up cultures. Of the 9 patients with positive nasal cultures during the study, 8 had only one positive culture. There was no significant difference in the mean yearly peritonitis rate or S aureus peritonitis rate (January 1995-May 1998). However, there was a significant decrease in the mean yearly exit-site infection rates both overall (from 8.8 episodes per 100 patients dialyzed per month in 1995 to 4.0 in 1998; P=.008) and due to S aureus (from 5.6 in 1995 to 0.9 in 1998; P=.03). Adverse effects of nasal mupirocin were mild overall; 1 patient was removed from the study due to an allergic reaction to mupirocin.

Conclusions:

Among CAPD patients who were S aureus nasal carriers, periodic brief treatment with nasal mupirocin after an initial eradication regimen kept them free of carriage, for the most part, with few adverse effects. The pulse mupirocin regimen offers simplicity and possibly better compliance, as well as minimizing exposure to this agent, thereby possibly reducing the risk of resistance. Further studies are warranted to compare this regimen to other commonly used mupirocin maintenance regimens in dialysis patients.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 20 , Issue 11 , November 1999 , pp. 741 - 745
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Holley, JL, Bernardini, J, Piraino, B. Infecting organisms in continuous ambulatory peritoneal dialysis patients on the Y-set. Am J Kidney Dis 1994;23:569–573.CrossRefGoogle ScholarPubMed
2. Kluytmans, J, van Belkum, A, Verbrugh, H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505–520.CrossRefGoogle ScholarPubMed
3. Sewell, CM, Clarridge, J, Lacke, C, Weinman, EJ, Young, EJ. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA 1982;248:1493–1495.CrossRefGoogle ScholarPubMed
4. Davies, SJ, Ogg, CS, Cameron, JS, Poston, S, Noble, WC. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Pent Diallnt 1989;9:61–64.Google ScholarPubMed
5. Luzar, MA, Coles, GA, Faller, B, Slingeneyer, A, Dah, GD, Briat, C, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990;322:505–509.CrossRefGoogle ScholarPubMed
6. Piraino, B, Perlmutter, JA, Holley, JL, Bernardini, J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial lnt 1993;13(suppl 2):S332–S334.Google ScholarPubMed
7. Herwaldt, LA. Staphylococcus aureus nasal carriage: role in continuous ambulatory peritoneal dialysis-associated infections. Perit Dial lnt 1993;13(suppl 2):S301–S305.CrossRefGoogle ScholarPubMed
8. Lye, WC, Leong, SO, van der Straaten, J, Lee, EJ. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv Perit Dial 1994;10:163–165.Google ScholarPubMed
9. Oxton, IX, Zimmerman, SW, Roecker, EB, Wakeen, M. Risk factors for peritoneal dialysis-related infections. Perit Dial lnt 1994;14:137–144.CrossRefGoogle ScholarPubMed
10. Zimmerman, SW, Ahrens, E, Johnson, CA, Craig, W, Leggett, J, O'Brien, M, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991;18:225–231.CrossRefGoogle ScholarPubMed
11. Perez-Fontan, M, Garcia-Falcon, T, Rosales, M, Rodriguez-Carmona, A, Adeva, M, Rodriguez-Lozano, I, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993;22:708–712.CrossRefGoogle ScholarPubMed
12. Bernardini, J, Piraino, B, Holley, J, Johnston, JR, Lutes, R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996;27:695–700.CrossRefGoogle Scholar
13. The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996;7:2403–2408.CrossRefGoogle Scholar
14. Boyce, JM. Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 1996;17:775–779.CrossRefGoogle ScholarPubMed
15. Hudson, IR. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect 1994;27:81–98.CrossRefGoogle ScholarPubMed
16. Thodis, E, Bhaskaran, S, Pasadakis, P, Bargman, JM, Vas, SI, Oreopoulos, DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial lnt 1998;18:261–270.Google ScholarPubMed
17. Turner, K, Uttley, L, Scrimgeour, A, McKewan, A, Gokal, R Natural history of Staphylococcus aureus nasal carriage and its relationship to exit-site infection. Perit Dial lnt 1998;18:271–273.Google ScholarPubMed
18. Vychytil, A, Lorenz, M, Schneider, B, Horl, WH, Haag-Weber, M. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients. J Am Soc Nephrol 1998;9:669–676.CrossRefGoogle ScholarPubMed